口服二甲双胍与2型糖尿病患者大肠腺瘤发生风险的荟萃分析与系统评价  

Oral metformin and the risk of colorectal adenoma:a systematic review and meta-analysis

作　　者：尹朝晖[1] 王静[1] 于磊 

机构地区：[1]济南军区总医院内分泌科,250031 [2]山东省立第三医院CT室,济南250031

出　　处：《中华消化病与影像杂志（电子版）》2017年第4期183-187,共5页Chinese Journal of Digestion and Medical Imageology(Electronic Edition)

摘　　要：目的有相关分析显示口服二甲双胍能降低大肠癌发生风险,但尚不明确是否与大肠腺瘤发生有关,故而通过荟萃分析进一步阐明二者相关性。方法检索Pubmed、Embase、the Cochrane Library、中国医学文献数据库中符合纳入标准的所有文献至2017年6月,由2位作者对检索数据进行提取,运用Stata 12.0软件对数据进行统计分析。结果共有10篇观察性研究纳入此次荟萃分析,结果显示口服二甲双胍与大肠腺瘤之间关系OR=0.74,95%CI(0.58~0.90),I^2=61.9%,P=0.05,亚组分析分为病例对照组和队列研究组,其OR值分别为:OR=1.04,95%CI(0.77~1.31),I^2=0,P=0.372,OR=0.66,95%CI(0.49~0.84),I2=65%,P=0.009。结论口服二甲双胍能减少大肠腺瘤的发生率。Objective Some studies indicate that oral metformin can significantly decrease the riskof colorectal cancer,but it is unclear whether it protects against colorectal adenoma. So we further clarify the correlation between the two factors by means of Meta analysis. Metliods We searched the control trialsmeeting the inclusion criteria through the PubMed, EMBase, the Cochrane Library,SinoMed published beJune 2017. Two authors independently retrieved the databases and extracted the data. Stata 12. 0 software wasused to analyze the data. Results Ten studies were included in this Meta- analysis. The results indicated thatoral metformin could decrease the risk of colorectal adenoma （ OR = 0.74,95% CI（ 0.58-0.90 ） , I^2 =61.9%,P = 0.05）. We divided the papers into two subgroups case-control study and retrospective cohortstudy,and the results were as follows ： OR = 1. 04,95% CI（0. 77-1. 31 ） ,I^2 = 0,P = 0. 372 ; OR =0. 66,95%CI（ 0. 49-0. 84 ）,I^2 = 65%,P = 0. 009. Conclusion Oral metformin can decrease the risk of colorectaladenoma.

关 键 词：糖尿病 2型 二甲双胍 大肠腺瘤 荟萃分析 

分 类 号：R587.1[医药卫生—内分泌] R735.34[医药卫生—内科学]